BIBW2992(Afatinib),EGFRInhibitor M60065-5s|产品详情|进口橙子视频旧款采购网

您好，欢迎来到橙子视频app安卓下载生物网站！请登录注册

我的订单 | 联系橙子视频app安卓下载 | 在线客服QQ：3012681483 | 客服电话：400-968-7988 | 工作时间：08:30-17:30

主营产品： ELISA91橙子视频、抗体、补体血清、兔补体、干扰素、小鼠测温仪、进口橙子视频旧款、Quidel代理、Swant代理、PBL Assay Science代理

网站首页产品中心代理品牌新闻资讯资源中心关于橙子视频app安卓下载

所在位置：首页 > 产品中心 > Xcessbio > Xcessbio产品

订购信息

上海橙子视频app安卓下载生物科技公司

Tel:400-968-7988 021-33779008

BIBW2992(Afatinib),EGFRInhibitor

品牌：Xcessbio

货号：M60065-5s

规格：5 mg solid

货期：

应用：

咨询客服

立即购买加入购物车

BIBW2992(Afatinib),EGFRInhibitor

商品详情参考文献相关资料

Product Information

Molecular Weight:	485.94
Formula:	C₂₄H₂₅ClFN₅O₃
Purity:	≥98%
CAS#:	439081-18-2
Solubility:	DMSO up to 100 mM
Chemical Name:	(S,E)-N-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide
Storage:	Powder: 4^oC 1 year. DMSO: 4^oC 3 month; -20^oC 1 year.

Biological Activity:

BIBW2992 (Afatinib) is a highly potent and selective irreversible EGFR inhibitor, inhibiting EGFR^wt, EGFR^L858R, EGFR^L858R/T790Mand HER2 with IC₅₀ of 0.5 nM, 0.4 nM, 10 nM, 14 nM, respectively. BIBW2992 suppresses transformation in isogenic cell-based assays, inhibits survival of cancer cell lines, exhibits potent effects on both EGFR and HER2 phosphorylation, and induces tumor regression in xenograft and transgenic lung cancer models, with superior activity over erlotinib. BIBW2992 is currently undergoing Phase III clinical trials for non-small cell lung carcinoma (NSCLC) and breast cancer.

How to Use:

In vitro: BIBW2992 was used at 1-10 µM final concentration in vitro and in cellular assays.

In vivo: BIBW2992 was orally dosed to mice at 20 mg/kg once per day, or in combination with 2 mg/kg of Rapamycin to significantly reduce the tumor volume. Formulation: 0.5% methylcellulose/0.4% Tween-80.

Reference:

1. Li D, et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. (2008) Oncogene. 27(34):4702-11.
2. Perera SA, et al. HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy. (2009) Proc Natl Acad Sci U S A. 106(2):474-9.
3. Khelwatty SA, et al. Growth response of human colorectal tumour cell lines to treatment with afatinib (BIBW2992), an irreversible erbB family blocker, and its association with expression of HER family members. (2011) Int J Oncol. 39(2):483-91.
4. Solca F, et al. Target Binding Properties and Cellular Activity of Afatinib (BIBW 2992), an Irreversible ErbB Family Blocker. (2012) J Pharmacol Exp Ther. 343(2):342-50.

Products are for research use only. Not for human use.

热销产品